4-Bromo-2-chlorobenzotrifluoride | CAS:467435-07-0

We serve 4-Bromo-2-chlorobenzotrifluoride CAS:467435-07-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Bromo-2-chlorobenzotrifluoride

Chemical Name:4-Bromo-2-chlorobenzotrifluoride
CAS.NO:467435-07-0
Synonyms:4-Bromo-2-chlorobenzotrifluoride
4-Bromo-2-chloro-1-(trifluoromethyl)benzene
4-Bromo-2-chloro-α,α,α-trifluorotoluene
 
Physical and Chemical Properties:
Density 1.7±0.1 g/cm3
Boiling Point 224.1±35.0 °C at 760 mmHg
Molecular Formula C7H3BrClF3
Molecular Weight 259.451
Flash Point 89.3±25.9 °C
Vapour Pressure 0.1±0.4 mmHg at 25°C
Index of Refraction 1.492
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 4-Bromo-2-chlorobenzotrifluoride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Bromo-2-chloro-α,α,α-trifluorotoluene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Bromo-2-chlorobenzotrifluoride Use and application,4-Bromo-2-chloro-1-(trifluoromethyl)benzene technical grade,usp/ep/jp grade.


Related News: The KCDC said a 28-year-old man had tested positive. He was among the 368 repatriated South Koreans who arrived from Wuhan on a charter flight on January 31. The rest of the evacuees have tested negative for the coronavirus.Difurfurylsulfide manufacturer Any drug or medication is composed of two components.2-amino-5-methylphenol supplier Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.5-Amino-2,4,6-triiodoisophthalic acid vendor Italy and Vietnam included Taiwan in banning flights from China, a move that they announced after the W.H.O. declared the coronavirus outbreak a global health emergency.The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%.